COVID-19 studies for: C19 studies:  HC QHC Q IvermectinIVM Vitamin DVitamin D ZincZn REGN-COV2REGN LY-CoVLY RemdesivirRMD
HC Q study #79
Source   Share   Tweet
See all 181 studies
Early treatment study
Chowdhury et al., Research Square, doi:10.21203/ (Preprint)
A Randomized Trial of Ivermectin-Doxycycline and Hydroxych loroquine-Azithromycin therapy on COVID19 patients
Small 116 patient RCT comparing Ivermectin-Doxycycline and HC Q+AZ, not showing a significant difference in time to PCR negative or symptom resolution. Time to symptomatic recovery was 5.93 days for Ivermectin-Doxycycline vs. 6.99 days for HC Q+AZ. Given the long half-life of HC Q and the lack of a loading dose, it may take several days for HC Q to reach therapeutic levels. 10% of HC Q+AZ patients were lost to followup (2x Ivermectin-Doxycycline). There is no comparison with a control group.
Source   Share   Tweet
See all 181 studies
Please send us corrections, updates, or comments.